The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Dual αvβ3 and αvβ5 blockade attenuates fibrotic and vascular alterations in a murine model of systemic sclerosis
Abstract
Systemic sclerosis (SSc) is a connective tissue disorder characterized by fibroblast activation and fibrosis of the skin and internal organs. Alterations in cell–integrin interaction are sufficient to initiate profibrotic processes. SSc fibroblasts express both αvβ3 and αvβ5 integrins and their activation induces myofibroblasts differentiation. The aim of the present study was to evaluate the effect of the anb3 and anb5 inhibitor, cilengitide, on the development of vascular and fibrotic changes in the chronic oxidant stress murine model of systemic sclerosis. SSc was induced in BALB/c mice by daily s.c. injections of HOCl for 6 weeks. Mice were randomized in three arms: HOCl alone (n=8), HOCl + Cilengitide (n=8), or Vehicle alone (n=8). Treatment with cilengitide 20 (mg/kg/i.p./day) was started 4 weeks after the first administration of HOCl and maintained throughout the remaining experimental period (2 weeks). Lung, skin, and heart fibrosis were evaluated by histology while kidney morphology by PAS staining. Collagen type I, focal adhesion kinase (FAK), and a-SMA were evaluated by immunostaining and p-FAK and TGF-β1 by Western blot and gene expression. Both cutaneous and pulmonary fibrosis induced by HOCl were attenuated by cilengitide treatment. Cilengitide administration reduced a-SMA, TGF-β1, and p-FAK expression and the increased deposition of fibrillar collagen in the heart and prevented glomeruli collapse in the kidneys. The inhibition of aνβ3 and aνβ5 integrin signaling prevented systemic fibrosis and renal vascular abnormalities in the reactive oxygen species model of SSc. Integrins aνβ3 and aνβ5 could prove useful as a therapeutic target in SSc.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For example, Cilengitide, an avb3/b5 antagonist, blocks immune cell adhesion and migration,inhibiting TGF-b -dependent myofibroblast differentiation, significantly reducing inflammatory infiltration and collagen deposition in liver and lung fibrosis models (130, 131).”
From The mechanotransduction-immune axis in organ fibrosis: dual regulatory mechanisms and translational therapeutic perspectives (2025) · doi:10.3389/fimmu.2025.1670213 · cites this paper as [130]
Citations
Cites
Simple method of estimating severity of pulmonary fibrosis on a numerical scale.
Ashcroft, T., Simpson, J. M., & Timbrell, V (1988) · Journal of Clinical Pathology · doi:10.1136/jcp.41.4.467 · Cited by 1,680
Guidelines for reporting experiments involving animals: the ARRIVE guidelines
McGrath, J., Drummond, G., McLachlan, E., Kilkenny, C., & Wainwright, C. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.00873.x · Cited by 1,592
Changes in causes of death in systemic sclerosis, 1972–2002
Steen, V. D., & Medsger, T. A. (2007) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2006.066068 · Cited by 1,528
Stupp, R., Hegi, M. E., Gorlia, T., Erridge, S. C., Perry, J., Hong, Y.-K., Aldape, K. D., Lhermitte, B., Pietsch, T., Grujicic, D., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70379-1 · Cited by 1,052
Mechanisms of Mechanotransduction
Orr, A. W., Helmke, B. P., Blackman, B. R., & Schwartz, M. A. (2006) · Developmental Cell · doi:10.1016/j.devcel.2005.12.006 · Cited by 798
Partial Inhibition of Integrin αvβ6 Prevents Pulmonary Fibrosis without Exacerbating Inflammation
Horan, G. S., Wood, S., Ona, V., Li, D. J., Lukashev, M. E., Weinreb, P. H., Simon, K. J., Hahm, K., Allaire, N. E., Rinaldi, N. J., et al. (2008) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200706-805oc · Cited by 420
Understanding fibrosis in systemic sclerosis: shifting paradigms, emerging opportunities
Bhattacharyya, S., Wei, J., & Varga, J. (2012) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2011.149 · Cited by 381
Hinz, B. (2009) · Current Rheumatology Reports · doi:10.1007/s11926-009-0017-1 · Cited by 373
Cross Talk among TGF- Signaling Pathways, Integrins, and the Extracellular Matrix
Munger, J. S., & Sheppard, D. (2011) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a005017 · Cited by 372
Mutations in Fibrillin-1 Cause Congenital Scleroderma: Stiff Skin Syndrome
Loeys, B. L., Gerber, E. E., Riegert-Johnson, D., Iqbal, S., Whiteman, P., McConnell, V., Chillakuri, C. R., Macaya, D., Coucke, P. J., De Paepe, A., et al. (2010) · Science Translational Medicine · doi:10.1126/scitranslmed.3000488 · Cited by 243
Cited by
Targeting integrin pathways: mechanisms and advances in therapy
Pang, X., He, X., Qiu, Z., Zhang, H., Xie, R., Liu, Z., Gu, Y., Zhao, N., Xiang, Q., & Cui, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01259-6 · Cited by 1,275
TGF-β signaling in health, disease and therapeutics
Deng, Z., Fan, T., Xiao, C., Tian, H., Zheng, Y., Li, C., & He, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01764-w · Cited by 1,168
Emerging therapeutic opportunities for integrin inhibitors
Slack, R. J., Macdonald, S. J. F., Roper, J. A., Jenkins, R. G., & Hatley, R. J. D. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00284-4 · Cited by 540
Myofibroblasts: Function, Formation, and Scope of Molecular Therapies for Skin Fibrosis
Tai, Y., Woods, E. L., Dally, J., Kong, D., Steadman, R., Moseley, R., & Midgley, A. C. (2021) · Biomolecules · doi:10.3390/biom11081095 · Cited by 240
Type V Collagen in Scar Tissue Regulates the Size of Scar after Heart Injury
Yokota, T., McCourt, J., Ma, F., Ren, S., Li, S., Kim, T.-H., Kurmangaliyev, Y. Z., Nasiri, R., Ahadian, S., Nguyen, T., et al. (2020) · Cell · doi:10.1016/j.cell.2020.06.030 · Cited by 209
“We subjected Col5a1CKO to ischemic cardiac injury and injected cilengitide or vehicle at 20mg/kg daily (Bagnato et al., 2018) for 14 days starting from the day of injury (Figure 7G).”
Method
Metadata
- Authors
- Bagnato, G. L., Irrera, N., Pizzino, G., Santoro, D., Roberts, W. N., Bagnato, G., Pallio, G., Vaccaro, M., Squadrito, F., Saitta, A., Altavilla, D., & Bitto, A.
- Affiliations
- Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy
- University of Messina (IT)
- University of Louisville (US)
- Corresponding author
- Bitto, Alessandra
- ORCID
- Venue
- Clinical Science
- Publisher
- Portland Press Ltd.
- Published
- 2018-01-19
- Volume
- 132
- Issue
- 2
- Pages
- 231-242
- ISSN
- 0143-5221 (ISSN-L)
- 1470-8736
- OpenAlex
- W2772987505
- Cited by
- 51
- References
- 42
- Citations by year
- 2026: 5 · 2025: 8 · 2024: 7 · 2023: 14 · 2022: 4 · 2021: 6 · 2020: 2 · 2019: 3 · 2018: 2
- FWCI
- 1.50
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Science (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Rheumatology › Systemic Sclerosis and Related Diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Connective tissue disorders research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Keywords
- systemic sclerosis, cilengitide, integrin αvβ3, integrin αvβ5, integrin blockade, fibrosis, pulmonary fibrosis, skin fibrosis, renal fibrosis, vascular anomalies, myofibroblast differentiation, focal adhesion kinase, TGF-β1, reactive oxygen species, oxidative stress, therapeutic target
- MeSH terms
- Animals, Arteries, Disease Models, Animal, Female, Fibrosis, Humans, Mice, Inbred BALB C, Pulmonary Fibrosis, Scleroderma, Systemic, Skin, Snake Venoms, Gene Expression, Receptors, Vitronectin, Integrin alphaVbeta3, Transforming Growth Factor beta1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Dual αvβ3 and αvβ5 blockade attenuates fibrotic and vascular alterations in a murine model of systemic sclerosis. https://app.cochat.ai/papers/10.1042/cs20171426
- The paper
- Bagnato, G. L., Irrera, N., Pizzino, G., Santoro, D., Roberts, W. N., Bagnato, G., Pallio, G., Vaccaro, M., Squadrito, F., Saitta, A., Altavilla, D., & Bitto, A. (2018). Dual αvβ3 and αvβ5 blockade attenuates fibrotic and vascular alterations in a murine model of systemic sclerosis. Clinical Science. https://doi.org/10.1042/cs20171426
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.